STAT5-mediated expression of oncogenic miR-155 in cutaneous T-cell lymphoma

Cell Cycle

Volumn 12, Issue 12, 2013, Pages 1939-1947

  Kopp, Katharina L ^a   Ralfkiaer, Ulrik ^b   Gjerdrum, Lise Mette R ^b   Helvad, Rikke ^a   Pedersen, Ida H ^a   Litman, Thomas ^a   Jønson, Lars ^a   Hagedorn, Peter H ^c   Krejsgaard, Thorbjørn ^a   Gniadecki, Robert ^d   Bonefeld, Charlotte M ^a   Skov, Lone ^e   Geisler, Carsten ^a   Wasik, Mariusz A ^f   Ralfkiaer, Elisabeth ^b   Odum, Niels ^a   Woetmann, Anders ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b Mental Health Services CPH   (Denmark)

^c Santaris Pharma AS   (Denmark)

^d BISPEBJERG HOSPITAL   (Denmark)

^e GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

BIC; CTCL; JAK; MF; MiR 155; MiRNA; STAT5

Indexed keywords

INTERLEUKIN 15; INTERLEUKIN 2; JANUS KINASE INHIBITOR; MICRORNA 155; STAT5 PROTEIN;

ARTICLE; CUTANEOUS T CELL LYMPHOMA; HUMAN; HUMAN CELL; PATHOGENESIS; PROTEIN EXPRESSION; T LYMPHOCYTE;

EID: 84879398642     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.24987     Document Type: Article

References (54)

1. Xiao C, Rajewsky K. MicroRNA control in the immune system: Basic principles. Cell 2009; 136:26-36; PMID:19135886; http://dx.doi.org/10.1016/j. cell.2008.12.027
2. Rodriguez A, Vigorito E, Clare S, Warren MV, Couttet P, Soond DR, et al. Requirement of bic/microRNA-155 for normal immune function. Science 2007; 316:608-11; PMID:17463290; http://dx.doi.org/10.1126/science. 1139253 (Pubitemid 46683148)
3. Ventura A, Jacks T. MicroRNAs and cancer: Short RNAs go a long way. Cell 2009; 136:586-91; PMID:19239879; http://dx.doi.org/10.1016/j.cell.2009.02.005
4. Eis PS, Tam W, Sun L, Chadburn A, Li Z, Gomez MF, et al. Accumulation of miR-155 and BIC RNA in human B cell lymphomas. Proc Natl Acad Sci USA 2005; 102:3627-32; PMID:15738415; http://dx.doi.org/10.1073/pnas.0500613102 (Pubitemid 40354662)
5. Yamanaka Y, Tagawa H, Takahashi N, Watanabe A, Guo YM, Iwamoto K, et al. Aberrant overexpression of microRNAs activate AKT signaling via downregulation of tumor suppressors in natural killercell lymphoma/leukemia. Blood 2009; 114:3265-75; PMID:19641183; http://dx.doi.org/10.1182/blood-2009-06-222794
6. Jiang S, Zhang HW, Lu MH, He XH, Li Y, Gu H, et al. MicroRNA-155 functions as an OncomiR in breast cancer by targeting the suppressor of cytokine signaling 1 gene. Cancer Res 2010; 70:3119-27; PMID:20354188; http://dx.doi.org/10.1158/0008-5472.CAN-09-4250
7. Mattiske S, Suetani RJ, Neilsen PM, Callen DF. The oncogenic role of miR-155 in breast cancer. Cancer Epidemiol Biomarkers Prev 2012; 21:1236-43; PMID:22736789; http://dx.doi.org/10.1158/1055-9965.EPI-12-0173
8. Ryu JK, Hong SM, Karikari CA, Hruban RH, Goggins MG, Maitra A. Aberrant MicroRNA-155 expression is an early event in the multistep progression of pancreatic adenocarcinoma. Pancreatology 2010; 10:66-73; PMID:20332664; http://dx.doi.org/10.1159/000231984
9. Wang M, Zhang P, Li Y, Liu G, Zhou B, Zhan L, et al. The quantitative analysis by stem-loop real-time PCR revealed the microRNA-34a, microRNA-155 and microRNA-200c overexpression in human colorectal cancer. Med Oncol 2012; 29:3113-8; PMID:22562822; http://dx.doi.org/10.1007/s12032-012-0241-9
10. Haasch D, Chen YW, Reilly RM, Chiou XG, Koterski S, Smith ML, et al. T cell activation induces a noncoding RNA transcript sensitive to inhibition by immunosuppressant drugs and encoded by the proto-oncogene, BIC. Cell Immunol 2002; 217:78-86; PMID:12426003; http://dx.doi.org/10.1016/S0008-8749(02)00506-3 (Pubitemid 35352162)
11. O'Connell RM, Taganov KD, Boldin MP, Cheng G, Baltimore D, 'Connell RM. MicroRNA-155 is induced during the macrophage inflammatory response. Proc Natl Acad Sci USA 2007; 104:1604-9; PMID:17242365; http://dx.doi.org/10.1073/pnas. 0610731104 (Pubitemid 46214637)
12. Ceppi M, Pereira PM, Dunand-Sauthier I, Barras E, Reith W, Santos MA, et al. MicroRNA-155 modulates the interleukin-1 signaling pathway in activated human monocyte-derived dendritic cells. Proc Natl Acad Sci USA 2009; 106:2735-40; PMID:19193853; http://dx.doi.org/10.1073/pnas.0811073106
13. Tili E, Michaille JJ, Wernicke D, Alder H, Costinean S, Volinia S, et al. Mutator activity induced by microRNA-155 (miR-155) links inflammation and cancer. Proc Natl Acad Sci USA 2011; 108:4908-13; PMID:21383199; http://dx.doi.org/10.1073/pnas.1101795108
14. Valeri N, Gasparini P, Fabbri M, Braconi C, Veronese A, Lovat F, et al. Modulation of mismatch repair and genomic stability by miR-155. Proc Natl Acad Sci USA 2010; 107:6982-7; PMID:20351277; http://dx.doi.org/10.1073/pnas. 1002472107
15. Wang Y, Lee CG. MicroRNA and cancer-focus on apoptosis. J Cell Mol Med 2009; 13:12-23; PMID:19175697; http://dx.doi.org/10.1111/j.1582-4934.2008.00510. x
16. Willemze R, Jaffe ES, Burg G, Cerroni L, Berti E, Swerdlow SH, et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005; 105:3768-85; PMID:15692063; http://dx.doi.org/10.1182/blood-2004-09-3502 (Pubitemid 40656118)
17. Ralfkiaer U, Hagedorn PH, Bangsgaard N, Løvendorf MB, Ahler CB, Svensson L, et al. Diagnostic microRNA profiling in cutaneous T-cell lymphoma (CTCL). Blood 2011; 118:5891-900; PMID:21865341; http://dx.doi.org/10.1182/ blood-2011-06-358382
18. van Kester MS, Ballabio E, Benner MF, Chen XH, Saunders NJ, van der Fits L, et al. miRNA expression profiling of mycosis fungoides. Mol Oncol 2011; 5:273-80; PMID:21406335; http://dx.doi.org/10.1016/j.molonc.2011.02.003
19. Nasu K, Said J, Vonderheid E, Olerud J, Sako D, Kadin M. Immunopathology of cutaneous T-cell lymphomas. Am J Pathol 1985; 119:436-47; PMID:3893149 (Pubitemid 15051892)
20. Waldmann TA. T-cell receptors for cytokines: Targets for immunotherapy of leukemia/lymphoma. Ann Oncol 2000; 11(Suppl 1):101-6; PMID:10707789; http://dx.doi.org/10.1093/annonc/11.suppl-1.S101
21. Zhang Q, Nowak I, Vonderheid EC, Rook AH, Kadin ME, Nowell PC, et al. Activation of Jak/STAT proteins involved in signal transduction pathway mediated by receptor for interleukin 2 in malignant T lymphocytes derived from cutaneous anaplastic large T-cell lymphoma and Sezary syndrome. Proc Natl Acad Sci USA 1996; 93:9148-53; PMID:8799169; http://dx.doi.org/10.1073/pnas.93.17.9148
22. Marzec M, Halasa K, Kasprzycka M, Wysocka M, Liu X, Tobias JW, et al. Differential effects of interleukin-2 and interleukin-15 versus interleukin-21 on CD4+ cutaneous T-cell lymphoma cells. Cancer Res 2008; 68:1083-91; PMID:18281483; http://dx.doi.org/10.1158/0008-5472.CAN-07-2403 (Pubitemid 351272226)
23. Qin JZ, Zhang CL, Kamarashev J, Dummer R, Burg G, Döbbeling U. Interleukin-7 and interleukin-15 regulate the expression of the bcl-2 and c-myb genes in cutaneous T-cell lymphoma cells. Blood 2001; 98:2778-83; PMID:11675351; http://dx.doi.org/10.1182/blood.V98.9.2778
24. Yamanaka K, Clark R, Rich B, Dowgiert R, Hirahara K, Hurwitz D, et al. Skin-derived interleukin-7 contributes to the proliferation of lymphocytes in cutaneous T-cell lymphoma. Blood 2006; 107:2440-5; PMID:16322477; http://dx.doi.org/10.1182/blood-2005-03-1139 (Pubitemid 43345565)
25. Döbbeling U, Dummer R, Laine E, Potoczna N, Qin JZ, Burg G. Interleukin-15 is an autocrine/paracrine viability factor for cutaneous T-cell lymphoma cells. Blood 1998; 92:252-8; PMID:9639524 (Pubitemid 28303200)
26. Eriksen KW, Kaltoft K, Mikkelsen G, Nielsen M, Zhang Q, Geisler C, et al. Constitutive STAT3-activation in Sezary syndrome: Tyrphostin AG490 inhibits STAT3-activation, interleukin-2 receptor expression and growth of leukemic Sezary cells. Leukemia 2001; 15:787-93; PMID:11368440; http://dx.doi.org/10. 1038/sj.leu.2402093 (Pubitemid 32492702)
27. Sommer VH, Clemmensen OJ, Nielsen O, Wasik M, Lovato P, Brender C, et al. In vivo activation of STAT3 in cutaneous T-cell lymphoma. Evidence for an antiapoptotic function of STAT3. Leukemia 2004; 18:1288-95; PMID:15141228; http://dx.doi.org/10.1038/sj.leu.2403385 (Pubitemid 39023140)
28. Nielsen M, Nissen MH, Gerwien J, Zocca MB, Rasmussen HM, Nakajima K, et al. Spontaneous interleukin-5 production in cutaneous T-cell lymphoma lines is mediated by constitutively activated Stat3. Blood 2002; 99:973-7; PMID:11807001; http://dx.doi.org/10.1182/blood.V99.3.973 (Pubitemid 34525560)
29. Krejsgaard T, Ralfkiaer U, Clasen-Linde E, Eriksen KW, Kopp KL, Bonefeld CM, et al. Malignant cutaneous T-cell lymphoma cells express IL-17 utilizing the Jak3/Stat3 signaling pathway. J Invest Dermatol 2011; 131:1331-8; PMID:21346774; http://dx.doi.org/10.1038/jid.2011.27
30. Krejsgaard T, Vetter-Kauczok CS, Woetmann A, Lovato P, Labuda T, Eriksen KW, et al. Jak3-and JNK-dependent vascular endothelial growth factor expression in cutaneous T-cell lymphoma. Leukemia 2006; 20:1759-66; PMID:16932349; http://dx.doi.org/10.1038/sj.leu.2404350 (Pubitemid 44574987)
31. Abraham RM, Zhang Q, Odum N, Wasik MA. The role of cytokine signaling in the pathogenesis of cutaneous T-cell lymphoma. Cancer Biol Ther 2011; 12:1019-22; PMID:22236880; http://dx.doi.org/10.4161/cbt.12.12.18144
32. Brender C, Lovato P, Sommer VH, Woetmann A, Mathiesen AM, Geisler C, et al. Constitutive SOCS-3 expression protects T-cell lymphoma against growth inhibition by IFNalpha. Leukemia 2005; 19:209-13; PMID:15618960; http://dx.doi.org/10.1038/sj.leu.2403610 (Pubitemid 40220583)
33. van der Fits L, van Kester MS, Qin Y, Out-Luiting JJ, Smit F, Zoutman WH, et al. MicroRNA-21 expression in CD4+ T cells is regulated by STAT3 and is pathologically involved in Sézary syndrome. J Invest Dermatol 2011; 131:762-8; PMID:21085192; http://dx.doi.org/10.1038/jid.2010.349
34. Zhang Q, Wang HY, Liu X, Bhutani G, Kantekure K, Wasik M. IL-2R common gamma-chain is epigenetically silenced by nucleophosphin-anaplastic lymphoma kinase (NPM-ALK) and acts as a tumor suppressor by targeting NPM-ALK. Proc Natl Acad Sci USA 2011; 108:11977-82; PMID:21715655; http://dx.doi.org/10.1073/pnas. 1100319108
35. Qin JZ, Kamarashev J, Zhang CL, Dummer R, Burg G, Döbbeling U. Constitutive and interleukin-7-and interleukin-15-stimulated DNA binding of STAT and novel factors in cutaneous T-cell lymphoma cells. J Invest Dermatol 2001; 117:583-9; PMID:11564163; http://dx.doi.org/10.1046/j.0022-202x.2001.01436.x (Pubitemid 32955584)
36. Mitchell TJ, Whittaker SJ, John S. Dysregulated expression of COOH-terminally truncated Stat5 and loss of IL2-inducible Stat5-dependent gene expression in Sezary Syndrome. Cancer Res 2003; 63:9048-54; PMID:14695224 (Pubitemid 38064087)
37. Bloom T, Kuzel TM, Querfeld C, Guitart J, Rosen ST. Cutaneous T-cell lymphomas: A review of new discoveries and treatments. Curr Treat Options Oncol 2012; 13:102-21; PMID:22311555; http://dx.doi.org/10.1007/s11864-011-0179-8
38. Heinemeyer T, Wingender E, Reuter I, Hermjakob H, Kel AE, Kel OV, et al. Databases on transcriptional regulation: TRANSFAC, TRRD and COMPEL. Nucleic Acids Res 1998; 26:362-7; PMID:9399875; http://dx.doi.org/10.1093/nar/26.1.362
39. Yutaka Akiyama. "TFSEARCH: Searching Transcription Factor Binding Sites", http://www.rwcp. or.jp/papia/)
40. Imaizumi T, Tanaka H, Tajima A, Yokono Y, Matsumiya T, Yoshida H, et al. IFN-? and TNFa synergistically induce microRNA-155 which regulates TAB2/IP-10 expression in human mesangial cells. Am J Nephrol 2010; 32:462-8; PMID:20948191; http://dx.doi.org/10.1159/000321365
41. Izban KF, Ergin M, Qin JZ, Martinez RL, Pooley JR, Saeed S, et al. Constitutive expression of NFkappa B is a characteristic feature of mycosis fungoides: Implications for apoptosis resistance and pathogenesis. Hum Pathol 2000; 31:1482-90; PMID:11150373; http://dx.doi.org/10.1053/hupa.2000.20370 (Pubitemid 32047000)
42. Fantin VR, Loboda A, Paweletz CP, Hendrickson RC, Pierce JW, Roth JA, et al. Constitutive activation of signal transducers and activators of transcription predicts vorinostat resistance in cutaneous T-cell lymphoma. Cancer Res 2008; 68:3785-94; PMID:18483262; http://dx.doi.org/10.1158/0008-5472. CAN-07-6091
43. Heltemes-Harris LM, Willette MJ, Vang KB, Farrar MA. The role of STAT5 in the development, function, and transformation of B and T lymphocytes. Ann NY Acad Sci 2011; 1217:18-31; PMID:21276004; http://dx.doi.org/10.1111/j.1749-6632. 2010.05907.x
44. Lin TS, Mahajan S, Frank DA. STAT signaling in the pathogenesis and treatment of leukemias. Oncogene 2000; 19:2496-504; PMID:10851048; http://dx.doi.org/10.1038/sj.onc.1203486 (Pubitemid 30339205)
45. Koptyra M, Gupta S, Talati P, Nevalainen MT. Signal transducer and activator of transcription 5a/b: Biomarker and therapeutic target in prostate and breast cancer. Int J Biochem Cell Biol 2011; 43:1417-21; PMID:21704724; http://dx.doi.org/10.1016/j.biocel. 2011.06.007
46. Kutty RK, Nagineni CN, Samuel W, Vijayasarathy C, Hooks JJ, Redmond TM. Inflammatory cytokines regulate microRNA-155 expression in human retinal pigment epithelial cells by activating JAK/STAT pathway. Biochem Biophys Res Commun 2010; 402:390-5; PMID:20950585; http://dx.doi.org/10.1016/j.bbrc.2010.10.042
47. Meinke A, Barahmand-Pour F, Wöhrl S, Stoiber D, Decker T. Activation of different Stat5 isoforms contributes to cell-type-restricted signaling in response to interferons. Mol Cell Biol 1996; 16:6937-44; PMID:8943349 (Pubitemid 26389753)
48. Gjerdrum LM, Woetmann A, Odum N, Burton CM, Rossen K, Skovgaard GL, et al. FOXP3+ regulatory T cells in cutaneous T-cell lymphomas: Association with disease stage and survival. Leukemia 2007; 21:2512-8; PMID:17713545; http://dx.doi.org/10.1038/sj.leu.2404913 (Pubitemid 350148895)
49. Kopp KL, Kauczok CS, Lauenborg B, Krejsgaard T, Eriksen KW, Zhang Q, et al. COX-2-dependent PGE(2) acts as a growth factor in mycosis fungoides (MF). Leukemia 2010; 24:1179-85; PMID:20428208; http://dx.doi.org/10.1038/leu.2010.66
50. Davis TH, Morton CC, Miller-Cassman R, Balk SP, Kadin ME. Hodgkin's disease, lymphomatoid papulosis, and cutaneous T-cell lymphoma derived from a common T-cell clone. N Engl J Med 1992; 326:1115-22; PMID:1532439; http://dx.doi.org/10.1056/NEJM199204233261704
51. Geisler C, Dietrich J, Nielsen BL, Kastrup J, Lauritsen JP, Odum N, et al. Leucine-based receptor sorting motifs are dependent on the spacing relative to the plasma membrane. J Biol Chem 1998; 273:21316-23; PMID:9694892; http://dx.doi.org/10.1074/jbc.273.33.21316 (Pubitemid 28385425)
52. Eriksen KW, Lovato P, Skov L, Krejsgaard T, Kaltoft K, Geisler C, et al. Increased sensitivity to interferon-alpha in psoriatic T cells. J Invest Dermatol 2005; 125:936-44; PMID:16297193
53. Yin Q, Wang X, McBride J, Fewell C, Flemington E. B-cell receptor activation induces BIC/miR-155 expression through a conserved AP-1 element. J Biol Chem 2008; 283:2654-62; PMID:18048365; http://dx.doi.org/10.1074/jbc. M708218200
54. Tang JZ, Zuo ZH, Kong XJ, Steiner M, Yin Z, Perry JK, et al. Signal transducer and activator of transcription (STAT)-5A and STAT5B differentially regulate human mammary carcinoma cell behavior. Endocrinology 2010; 151:43-55; PMID:19966185; http://dx.doi.org/10.1210/en.2009-0651